Medical Science Liaison - New England

Position Summary:

The Apellis MSL is a remote role focused on developing and maintaining peer-to-peer relationships with key medical experts. This role will primarily support the Apellis rare disease programs in hematology. The MSL will collaborate with physicians and other medical experts to support trial enrollment, provide program and protocol training and ensure that health care professionals have the most up to date information as the clinical development programs mature.

Key Responsibilities Include:

• Develop and maintain peer-to-peer collaborations and relationships with key medical experts in the rare disease community
• Support clinical development initiatives including site identification, trial recruitment, registry, and presentation of final approved data
• Collaborate with physicians on medical affairs initiatives including publications, advisory boards, medical education opportunities, training, and speaker development
• Serve as scientific peer-to-peer resource to external disease experts and internal stakeholders        
• Support the medical community with up-to-date medical information, robust disease expertise, and product information
• Communicate clinical insights on new data to Apellis Medical Affairs and to inform medical strategy for the therapeutic area.
• Train internal stakeholders on key scientific and medical topics in relevant therapeutic area
• Develop an understanding of the regional landscape including specialties involved in care of patients
• Maintain Effective and appropriate communication among internal stakeholders while maintaining full compliance with relevant requirements.
• Generate tactical regional plans to provide needs based, value-added support of the medical and scientific community in-line with company goals
• Uses systems to strategically map, identify, profile and prioritize thought leaders in line with the medical plan and goals.
• Maintain accurate reporting and documentation of MSL activities

Education, Registration & Certification:

• Bachelor’s degree in chemistry, biology, pharmacy, or other medical related discipline.
• Advanced degree preferred.

Experience:

• At least 5 years of experience in Medical Affairs or Medical Science role
• Robust and current clinical development experience supporting drugs to treat rare diseases; prior hematology and nephrology experience preferred
• Candidates must have well-established networks and active relationships with KOLs in the rare disease community
• Candidate must have an understanding of compliance considerations and demonstrate ability to work compliantly in a field-based role, within the medical organization, as well as across the commercial organization

Skills, Knowledge & Abilities:

• Excellent oral and written communication skills
• Energetically embraces responsibilities, demonstrates ability to achieve goals
• Has strong initiative, and functions well as part of a cross-functional team
• Exhibits excellent time management
• Demonstrated ability to work independently
• Excellent verbal and written communication skills
• Experience in a start-up environment preferred
• Must be pro-active team player, flexible, and ability to work in ambiguous situations

Physical Demands and Work Environment:

• Office is home based

Travel Requirements:

• Travel within region up to 75%.
• Required travel to medical meetings, team meetings, and other group meetings (will require some weekends)

Benefits and Perks:

Apellis offers a comprehensive benefits package, including a 401(k) plan with company match, inclusive family building benefits, flexible time off, summer and winter shutdowns, paid family leave, disability and life insurance, and more! Visit https://apellis.com/careers/ to learn more.

Company Background:

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. With nearly a dozen clinical and pre-clinical programs underway, we believe we have only begun to unlock the potential of targeting C3 across many serious diseases.

For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn